Cargando…

UK clinical guideline for the prevention and treatment of osteoporosis

INTRODUCTION: In 2008, the UK National Osteoporosis Guideline Group (NOGG) produced a guideline on the prevention and treatment of osteoporosis, with an update in 2013. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Compston, J., Cooper, A., Cooper, C., Gittoes, N., Gregson, C., Harvey, N., Hope, S., Kanis, J. A., McCloskey, E. V., Poole, K. E. S., Reid, D. M., Selby, P., Thompson, F., Thurston, A., Vine, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397452/
https://www.ncbi.nlm.nih.gov/pubmed/28425085
http://dx.doi.org/10.1007/s11657-017-0324-5
_version_ 1783230255921627136
author Compston, J.
Cooper, A.
Cooper, C.
Gittoes, N.
Gregson, C.
Harvey, N.
Hope, S.
Kanis, J. A.
McCloskey, E. V.
Poole, K. E. S.
Reid, D. M.
Selby, P.
Thompson, F.
Thurston, A.
Vine, N.
author_facet Compston, J.
Cooper, A.
Cooper, C.
Gittoes, N.
Gregson, C.
Harvey, N.
Hope, S.
Kanis, J. A.
McCloskey, E. V.
Poole, K. E. S.
Reid, D. M.
Selby, P.
Thompson, F.
Thurston, A.
Vine, N.
author_sort Compston, J.
collection PubMed
description INTRODUCTION: In 2008, the UK National Osteoporosis Guideline Group (NOGG) produced a guideline on the prevention and treatment of osteoporosis, with an update in 2013. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women and men age 50 years or over. METHODS: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence. RESULTS: Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment, lifestyle measures and pharmacological interventions, duration and monitoring of bisphosphonate therapy, glucocorticoid-induced osteoporosis, osteoporosis in men, postfracture care and intervention thresholds. CONCLUSION: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals who are involved in its management.
format Online
Article
Text
id pubmed-5397452
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-53974522017-05-04 UK clinical guideline for the prevention and treatment of osteoporosis Compston, J. Cooper, A. Cooper, C. Gittoes, N. Gregson, C. Harvey, N. Hope, S. Kanis, J. A. McCloskey, E. V. Poole, K. E. S. Reid, D. M. Selby, P. Thompson, F. Thurston, A. Vine, N. Arch Osteoporos Position Paper INTRODUCTION: In 2008, the UK National Osteoporosis Guideline Group (NOGG) produced a guideline on the prevention and treatment of osteoporosis, with an update in 2013. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women and men age 50 years or over. METHODS: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence. RESULTS: Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment, lifestyle measures and pharmacological interventions, duration and monitoring of bisphosphonate therapy, glucocorticoid-induced osteoporosis, osteoporosis in men, postfracture care and intervention thresholds. CONCLUSION: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals who are involved in its management. Springer London 2017-04-19 2017 /pmc/articles/PMC5397452/ /pubmed/28425085 http://dx.doi.org/10.1007/s11657-017-0324-5 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Position Paper
Compston, J.
Cooper, A.
Cooper, C.
Gittoes, N.
Gregson, C.
Harvey, N.
Hope, S.
Kanis, J. A.
McCloskey, E. V.
Poole, K. E. S.
Reid, D. M.
Selby, P.
Thompson, F.
Thurston, A.
Vine, N.
UK clinical guideline for the prevention and treatment of osteoporosis
title UK clinical guideline for the prevention and treatment of osteoporosis
title_full UK clinical guideline for the prevention and treatment of osteoporosis
title_fullStr UK clinical guideline for the prevention and treatment of osteoporosis
title_full_unstemmed UK clinical guideline for the prevention and treatment of osteoporosis
title_short UK clinical guideline for the prevention and treatment of osteoporosis
title_sort uk clinical guideline for the prevention and treatment of osteoporosis
topic Position Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397452/
https://www.ncbi.nlm.nih.gov/pubmed/28425085
http://dx.doi.org/10.1007/s11657-017-0324-5
work_keys_str_mv AT compstonj ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT coopera ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT cooperc ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT gittoesn ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT gregsonc ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT harveyn ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT hopes ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT kanisja ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT mccloskeyev ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT poolekes ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT reiddm ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT selbyp ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT thompsonf ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT thurstona ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT vinen ukclinicalguidelineforthepreventionandtreatmentofosteoporosis
AT ukclinicalguidelineforthepreventionandtreatmentofosteoporosis